Financial Survey: Proteon Therapeutics (PRTO) vs. The Competition

Proteon Therapeutics (NASDAQ: PRTO) is one of 285 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its rivals? We will compare Proteon Therapeutics to related companies based on the strength of its valuation, analyst recommendations, institutional ownership, dividends, profitability, risk and earnings.

Earnings & Valuation

This table compares Proteon Therapeutics and its rivals revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Proteon Therapeutics $2.95 million -$28.52 million -0.86
Proteon Therapeutics Competitors $284.28 million $34.29 million 81.41

Proteon Therapeutics’ rivals have higher revenue and earnings than Proteon Therapeutics. Proteon Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Volatility and Risk

Proteon Therapeutics has a beta of 1.62, suggesting that its stock price is 62% more volatile than the S&P 500. Comparatively, Proteon Therapeutics’ rivals have a beta of 6.06, suggesting that their average stock price is 506% more volatile than the S&P 500.

Profitability

This table compares Proteon Therapeutics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Proteon Therapeutics N/A -105.58% -77.60%
Proteon Therapeutics Competitors -5,311.19% -218.06% -39.34%

Analyst Ratings

This is a breakdown of current ratings and price targets for Proteon Therapeutics and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Proteon Therapeutics 0 7 1 0 2.13
Proteon Therapeutics Competitors 857 3201 11603 231 2.71

Proteon Therapeutics presently has a consensus target price of $3.33, indicating a potential upside of 75.00%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 43.92%. Given Proteon Therapeutics’ higher possible upside, analysts plainly believe Proteon Therapeutics is more favorable than its rivals.

Institutional and Insider Ownership

50.1% of Proteon Therapeutics shares are held by institutional investors. Comparatively, 50.2% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 36.3% of Proteon Therapeutics shares are held by company insiders. Comparatively, 17.1% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Proteon Therapeutics rivals beat Proteon Therapeutics on 8 of the 12 factors compared.

Proteon Therapeutics Company Profile

Proteon Therapeutics, Inc. is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The Company has completed Phase II trial of vonapanitase in patients undergoing creation of an arteriovenous fistula (AVF). The Company initiated the first of two Phase III trials, PATENCY-1, for vonapanitase in radiocephalic AVFs. Its vonapanitase product candidate is a recombinant human elastase under development as a treatment to prevent AVF and arteriovenous graft (AVG) patency loss.

Receive News & Ratings for Proteon Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply